Login / Signup

Comparison of Yearly Cost Related to Complications Between Deferasirox and Deferiprone Monotherapy in Thalassemia.

Teny Tjitra SariPustika Amalia WahidiyatLudi Dhyani RahmartaniStephen Diah IskandarIsyanaditta Agung Putri
Published in: Journal of pediatric hematology/oncology (2024)
Cardiomyopathy, diabetes mellitus, delayed puberty, and malnutrition were the most common complications found in the study. This study showed that deferiprone should be taken as consideration as a drug of choice to treat iron overload in thalassemia provided by Indonesian national health insurance which is less costly despite the probability of complications found after the treatment was given. Further investigations are required to evaluate contributing factors of complications in thalassemia.
Keyphrases
  • health insurance
  • risk factors
  • sickle cell disease
  • type diabetes
  • healthcare
  • adipose tissue
  • atrial fibrillation
  • metabolic syndrome
  • electronic health record
  • iron deficiency